Soleus Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Soleus Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-38,811	Closed	-$8.57M	–	99
2025 Q4	$8.57M	Sell	38,811 -455,000	-92%	-$73.5M	0.32%	53
2025 Q3	$47.3M	Buy	493,811 +31,000	+7%	+$1.98M	2.38%	15
2025 Q2	$22.5M	Buy	+462,811	New	+$11.1M	1.49%	23

Soleus Capital Management's CDTX Position: Q1 2026 in Review

Soleus Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 38,811 shares — an estimated $8.57M sold.

Soleus Capital Management first reported a position in CDTX in Q2 2025 and held it in 3 quarters. The position peaked at $47.3M in Q3 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Soleus Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Soleus Capital Management sold 38,811 Cidara Therapeutics shares in Q1 2026, an estimated $8.57M.
Soleus Capital Management first reported a position in Cidara Therapeutics in Q2 2025 and held it in 3 quarters.
Soleus Capital Management's Cidara Therapeutics position peaked at $47.3M in Q3 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.